UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

§ 240.13d-2(a)

(Amendment No. 13)¹

Pulse Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

74587B 10 1

(CUSIP Number)

ADAM W. FINERMAN, ESQ.

BAKER HOSTETLER LLP

45 Rockefeller Plaza

New York, New York 10111

(212) 589-4233

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

 

November 28, 2023

(Date of Event Which Requires Filing of This Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1

NAME OF REPORTING PERSON

ROBERT W. DUGGAN

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐

(b) ☐

3

SEC USE ONLY

4

SOURCE OF FUNDS

PF

5

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

☐

6

CITIZENSHIP OR PLACE OF ORGANIZATION

U.S.A

NUMBER OF

7

SOLE VOTING POWER

SHARES

BENEFICIALLY

37,454,260*

OWNED BY

8

SHARED VOTING POWER

EACH

REPORTING

- 0 -

PERSON WITH

9

SOLE DISPOSITIVE POWER

37,454,260*

10

SHARED DISPOSITIVE POWER

- 0 -

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

37,454,260*

12

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

☐

13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

67.8%*

14

TYPE OF REPORTING PERSON

IN

* Represents (i) 37,454,260 Shares, including 197,786 Shares underlying certain options, (ii) 492,069 Shares held by Genius Inc, and (iii) 212,944 Shares held by Blazon Corporation. This does not include options which are not exercisable in 60 days from the date hereof.

 

	1		NAME OF REPORTING PERSON
				GENIUS INC.
	2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP															(a) ☐
																		(b) ☐
	3		SEC USE ONLY
	4		SOURCE OF FUNDS
				WC
	5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)															☐
	6		CITIZENSHIP OR PLACE OF ORGANIZATION
				DELAWARE
NUMBER OF				7		SOLE VOTING POWER
SHARES
BENEFICIALLY							492,069
OWNED BY				8		SHARED VOTING POWER
EACH
REPORTING							- 0 -
PERSON WITH				9		SOLE DISPOSITIVE POWER
							492,069
				10		SHARED DISPOSITIVE POWER
							- 0 -
	11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
				492,069
	12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES															☐
	13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
				0.9%
	14		TYPE OF REPORTING PERSON
				CO

	1		NAME OF REPORTING PERSON
				BLAZON CORPORATION
	2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP															(a) ☐
																		(b) ☐
	3		SEC USE ONLY
	4		SOURCE OF FUNDS
				WC
	5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)															☐
	6		CITIZENSHIP OR PLACE OF ORGANIZATION
				CALIFORNIA
NUMBER OF				7		SOLE VOTING POWER
SHARES
BENEFICIALLY							212,944
OWNED BY				8		SHARED VOTING POWER
EACH
REPORTING							- 0 -
PERSON WITH				9		SOLE DISPOSITIVE POWER
							212,944
				10		SHARED DISPOSITIVE POWER
							- 0 -
	11		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
				212,944
	12		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES															☐
	13		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
				0.4%
	14		TYPE OF REPORTING PERSON
				CO

 

The following constitutes Amendment No. 13 to the Schedule 13D filed by the undersigned (the “Amendment No. 13”). This Amendment No. 13 amends the Schedule 13D as specifically set forth herein.

 

Item 3.

Source and Amount of Funds or Other Consideration.

Item 3 is hereby amended and restated to read as follows:

 

The aggregate purchase cost of the 37,454,260 Shares owned directly by Mr. Duggan is approximately $274,862,440, including brokerage commissions. Such Shares were acquired with personal funds. Mr. Duggan received his 197,786 stock options in connection with his service on the board of directors of the Issuer.  The aggregate purchase cost of the 492,069 Shares owned by Genius Inc., which Mr. Duggan is the sole shareholder of and may be deemed to be beneficially owned by Mr. Duggan, is approximately $4,471,896, including brokerage commissions. Such Shares were acquired with working capital. The aggregate purchase cost of the 212,944 Shares owned by Blazon Corporation, which Mr. Duggan is the majority shareholder of and may be deemed to be beneficially owned by Mr. Duggan, is approximately $1,938,227, including brokerage commissions. Such Shares were acquired with working capital.

 

Item 5.

Interest in Securities of the Issuer.

Items 5(a)-(c) are hereby amended to read as follows:

 

The aggregate percentage of Shares reported owned by each person named herein is based upon 55,080,527 Shares outstanding as of November 15, 2023, as reported in the Company’s definitive Proxy Statement filed with the SEC on November 27, 2023.

 

	A.	Genius Inc.
			a)	As of the close of business on November 30, 2023, Genius Inc. beneficially owned 492,069 Shares.
				Percentage: Approximately 0.9%

 

	b)	1. Sole power to vote or direct vote: 492,069
		2. Shared power to vote or direct vote: 0
		3. Sole power to dispose or direct the disposition: 492,069
		4. Shared power to dispose or direct the disposition: 0

  

			c)	Genius Inc. has not entered into any transactions in the Shares during the past sixty days.
	B.	Mr. Duggan
			a)	As of the close of business on November 30, 2023, Mr. Duggan directly owned 37,454,260 Shares, including 197,786 Shares underlying certain options exercisable within sixty days hereof. As the sole shareholder of Genius Inc., Mr. Duggan may be deemed the beneficial owner of the 492,069 Shares owned by Genius Inc. As the majority shareholder of Blazon Corporation, Mr. Duggan may be deemed the beneficial owner of the 212,944 Shares owned by Blazon Corporation
				Percentage: Approximately 67.8%

 

	b)	1. Sole power to vote or direct vote: 37,454,260
		2. Shared power to vote or direct vote: 0
		3. Sole power to dispose or direct the disposition: 37,454,260
		4. Shared power to dispose or direct the disposition: 0

 

c)

The transactions in the Shares by Mr. Duggan during the past sixty days are set forth below in the table entitled “Transactions in the Common Stock During the Past Sixty Days.”

 

 

	B.	Blazon Corporation
			a)	As of the close of business on November 30, 2023, Blazon Corporation beneficially owned 212,944 Shares.
				Percentage: Approximately 0.4%

 

	b)	1. Sole power to vote or direct vote: 212,944
		2. Shared power to vote or direct vote: 0
		3. Sole power to dispose or direct the disposition: 212,944
		4. Shared power to dispose or direct the disposition: 0

 

c)

The transactions in the Shares by Blazon Corporation during the past sixty days are set forth below in the table entitled “Transactions in the Common Stock During the Past Sixty Days.”

 

Transactions in the Common Stock During the Past Sixty Days
Reporting Person	Type of Security		Securities Purchased / (Sold)				Price Per Share($)				Date of Purchase / Sale
Blazon Corporation	Common Stock			152,944				9.06			11/30/2023
Blazon Corporation	Common Stock			60,000				9.21			11/29/2023
Mr. Duggan	Common Stock			1,667	*			5.95			11/29/2023
Mr. Duggan	Common Stock			158,600				9.44			11/29/2023
Mr. Duggan	Common Stock			124,397				8.98			11/28/2023
Mr. Duggan	Common Stock			241				6.10			11/17/2023
Mr. Duggan	Common Stock			10,000				6.09			11/17/2023
Mr. Duggan	Common Stock			10,000				6.11			11/17/2023
Mr. Duggan	Common Stock			13,265	*			5.95			11/7/2023
*Purchased pursuant to the exercise of stock options.

  

Item 7.

Material to be Filed as Exhibits.

 

Item 7 is hereby amended to add the following exhibit:

 

99.1	Joint Filing Agreement, dated December 4, 2023

 

 

SIGNATURES

 

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Dated: December 4, 2023

 

	GENIUS INC.
	By:	/s/ Martin Bittner
		Name:	Martin Bittner
		Title:	Chief Operating Officer
	BLAZON CORPORATION
	By:	/s/ Robert W. Duggan
		Name:	Robert W. Duggan
		Title:	Authorized Signatory

 

 

	/s/ Robert W. Duggan
	Robert W. Duggan

 

 

 

Exhibit 99.1

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par value, of Pulse Biosciences, Inc., a Nevada corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.

 

The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others. This joint filing agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

 

Date: December 4, 2023

 

	GENIUS INC.
	By:	/s/ Martin Bittner
		Name:	Martin Bittner
		Title:	Chief Operating Officer

        

	BLAZON CORPORATION
	By:	/s/ Robert W. Duggan
		Name:	Robert W. Duggan
		Title:	Authorized Signatory

 

 

	/s/ Robert W. Duggan
	Robert W. Duggan